Dr. Saenger on the Need for Immunotherapy Biomarkers

Yvonne M. Saenger, MD
Published: Wednesday, Aug 07, 2013

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the need for biomarkers for immunotherapies.

For a long time, immunotherapies were not effective at all, Saenger says. Now that effective immunotherapies exist, it is important to define which patients are most likely to see benefit. Additionally, it is important to define which patients will not likely see benefit, so that they can receive other treatments or different approaches.

In the case of ipilimumab (Yervoy) for melanoma, only about 5% of patients will see a long term response and 20% are alive at two years. Though the latest data suggest that 40% of patients may be alive at two years, this benefit is still not good enough, Saenger says. The oncology community hopes to develop agents that will help everyone and biomarkers that will help prioritize treatment for those most likely to see benefit.

SELECTED
LANGUAGE
Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the need for biomarkers for immunotherapies.

For a long time, immunotherapies were not effective at all, Saenger says. Now that effective immunotherapies exist, it is important to define which patients are most likely to see benefit. Additionally, it is important to define which patients will not likely see benefit, so that they can receive other treatments or different approaches.

In the case of ipilimumab (Yervoy) for melanoma, only about 5% of patients will see a long term response and 20% are alive at two years. Though the latest data suggest that 40% of patients may be alive at two years, this benefit is still not good enough, Saenger says. The oncology community hopes to develop agents that will help everyone and biomarkers that will help prioritize treatment for those most likely to see benefit.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x